Peptides. An Honest Guide

A peptide is a short chain of amino acids linked by peptide bonds. That is the same chemistry that builds every protein in your body. The line between peptide and protein is fuzzy on purpose. By IUPAC convention, chains of 10 or more residues are called polypeptides. Once a chain folds into a stable three-dimensional shape (usually around 50 residues, or roughly 5 kilodaltons), most chemists start calling it a protein. Insulin sits right on that border at 51 amino acids in two disulfide-linked chains, and gets called both.

What matters biologically is not the length. It is the chemistry. The peptide bond is a planar amide with about 40 percent double-bond character. That one fact decides how peptides fold, how they signal, and why your gut destroys most of them on contact. Almost all natural peptides are built from L-stereoisomer amino acids (the left-handed mirror image), and your digestive enzymes evolved to recognize that exact handedness.

Your body uses peptides as signaling molecules everywhere. Insulin controls blood sugar. Glucagon raises it. Oxytocin drives childbirth and social bonding. Vasopressin controls water retention. GnRH triggers reproductive hormones. Ghrelin signals hunger. GLP-1 is the gut hormone behind Ozempic and Wegovy. Somatostatin turns off other hormones. ANP and BNP regulate fluid balance and double as heart-failure markers. Beta-endorphin is your body's own opioid. Substance P signals pain.

Why most peptides get injected, not swallowed. Native peptides have plasma half-lives measured in minutes. Natural GLP-1 lasts about 1 to 2 minutes once released, before an enzyme called DPP-4 cuts it apart. The gut destroys them. Even oral semaglutide (Rybelsus, FDA-approved 2019) gets only about 1 percent of the dose into your bloodstream. It works because it is unusually potent. Most peptide drugs are injectables for a reason.

Peptide therapy has a hundred-year arc. Here are the turning points.

1921. Banting and Best at the University of Toronto isolate insulin from canine pancreas. The first peptide ever used as a human drug, and still the most important. Nobel 1923.

1953. Vincent du Vigneaud chemically synthesizes oxytocin, the first peptide hormone built from individual amino acids in a lab. Nobel 1955.

1963. Bruce Merrifield publishes solid-phase peptide synthesis in JACS, anchoring the growing chain to a polymer bead. This was the manufacturing leap that made every modern peptide drug commercially possible. Nobel 1984.

1982. FDA approves Humulin (Genentech / Eli Lilly), recombinant human insulin grown in E. coli. The first genetically engineered medicine ever approved, reviewed in five months versus the roughly 30-month average of the era.

1985. Doctors recognize iatrogenic Creutzfeldt-Jakob disease (a fatal prion brain disease) in young recipients of cadaver-derived pituitary growth hormone. The program shuts down. Recombinant somatropin (Genentech's Protropin, also 1985) replaces it.

1985 / 1988. FDA approves leuprolide, opening the GnRH-agonist era for prostate cancer and endometriosis. Then comes octreotide, the first somatostatin analog and a turning point in treating acromegaly.

1992. John Eng at the Bronx VA isolates exendin-4 from the saliva of Heloderma suspectum, the Gila monster. This desert lizard fasts for months without crashing its blood sugar. The molecule became the template for the entire GLP-1 drug class. Eng patented it himself because the VA would not.

1993. Predrag Sikiric in Zagreb describes BPC-157, a 15-amino-acid peptide claimed to be a fragment of a 'body protection compound' in human gastric juice. The entire grey-market 'research peptide' subculture traces back to this one Croatian lab.

2005 to 2022. The GLP-1 dynasty arrives in order: exenatide (Byetta, 2005), liraglutide (Victoza/Saxenda, 2010), semaglutide (Ozempic 2017, Wegovy 2021), tirzepatide (Mounjaro/Zepbound, a dual GIP/GLP-1, 2022). The Gila-monster lineage became the fastest-growing drug class in pharma history.

September 2023. FDA places a cluster of grey-market peptides into Category 2 of the 503A interim bulks list: BPC-157, TB-500/thymosin β4, MOTS-c, KPV, epitalon, Selank (status varies by FDA list iteration; check current 503A bulks tables), Semax, DSIP, AOD-9604, GHK-Cu (injectable), Melanotan II, PEG-MGF, CJC-1295 with DAC, ipamorelin, GHRP-2, GHRP-6, plus bulk-powder semaglutide and tirzepatide. US compounding pharmacies can no longer use them. The crackdown is on.

2024 to 2026. FDA declares the tirzepatide and semaglutide shortages resolved (Dec 2024 and Feb 2025), ending the grey legal route for compounded GLP-1s. More than 50 warning letters go out to telehealth GLP-1 sellers in a single day in September 2025. Another 30 follow in March 2026. Novo Nordisk sues Hims & Hers in February 2026, then settles a month later. In April 2026 the FDA removes 12 peptides from Category 2 pending an advisory-committee review in July 2026. That is not an approval. It is a return to 'under review'.

Hear 'peptide therapy' and many people picture grey-market vials and influencer protocols. The reality is the opposite. Peptides are one of the most established and tightly regulated drug classes in modern medicine. Roughly 100 peptide drugs are approved globally as of 2026, and they sit at the center of mainstream care.

Diabetes and obesity. Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta). All peptide drugs.

Hormone replacement. Insulin and its analogs (lispro, aspart, glargine, degludec). Glucagon (Baqsimi nasal, Gvoke SC) for severe hypoglycemia. Recombinant growth hormone (somatropin). Teriparatide (Forteo) and abaloparatide (Tymlos), both anabolic peptides for osteoporosis at fracture risk.

Prostate cancer and endometriosis. GnRH agonists: leuprolide (Lupron), goserelin (Zoladex), triptorelin. GnRH antagonists: degarelix (Firmagon), relugolix (Orgovyx, the first oral GnRH antagonist, FDA 2020).

Acromegaly and neuroendocrine tumors. Somatostatin analogs: octreotide (Sandostatin), lanreotide (Somatuline), pasireotide (Signifor).

Other approved indications. Desmopressin (DDAVP) for central diabetes insipidus and nocturnal enuresis. Setmelanotide (Imcivree) for rare genetic obesity. Bremelanotide (Vyleesi) for premenopausal HSDD (hypoactive sexual desire disorder). Linaclotide (Linzess) and plecanatide (Trulance) for IBS-with-constipation. Calcitonin (Miacalcin) for hypercalcemia and Paget's. Elamipretide (FDA 2025) for Barth syndrome, a mitochondria-targeted tetrapeptide.

Antibiotics that are peptides. Vancomycin (1958), daptomycin (2003), polymyxin B and colistin, teicoplanin. These are the backbone of MRSA, VRE, and Gram-negative bacterial therapy.

Two non-obvious facts. First, the entire GLP-1 phenomenon traces to Gila monster venom, a desert reptile that fasts for months. Second, oral peptides are no longer impossible. Oral semaglutide (Rybelsus, 2019) and oral octreotide (Mycapssa, 2020) broke the long-standing dogma that peptides only work by injection. The next decade of peptide drugs will increasingly be pills, not pens.

The 'peptide revolution' is not coming. It already happened, quietly, over forty years.

Outside the pharmacy, a very different conversation is happening. The grey-market peptide stack (sold by US compounding clinics, telehealth sites, and 'research peptide' vendors) usually includes:

• BPC-157. A 15-amino-acid synthetic peptide marketed for joint, tendon, and gut healing. Around 500 published papers exist. A recent audit found over 80 percent list Sikiric or Seiwerth (Univ. of Zagreb) as first or senior author. Independent replications in mainstream journals are sparse. Only three small pilot studies in humans have been published. No Phase II or III trial anywhere. Placed on FDA 503A Category 2 in September 2023 (FDA cited immunogenicity, peptide-related impurities, and no adequate human safety data). Added to the WADA S0 (non-approved substances) category effective 1 January 2022.
• Thymosin β4 / TB-500. Actin-binding peptide claimed to repair tissue. RegeneRx ran legitimate Phase 2 trials (paused for funding, not safety). Cat 2; WADA S2.
• Thymosin α1 (Tα1, Zadaxin). The strongest evidence on this list. Approved in 35+ countries (Italy for melanoma adjuvant, China for hepatitis B). Over 11,000 patients across published trials. Not FDA-approved.
• Sermorelin (GHRH 1-29). FDA-approved in the early 1990s as Geref for pediatric GH deficiency, then withdrawn by EMD Serono in December 2008 for manufacturing and commercial reasons, not safety (FDA Federal Register, 2013). Compounded only since then.
• Tesamorelin (Egrifta / Egrifta WR). Stabilized GHRH analog, FDA-approved 2010 for HIV-associated visceral lipodystrophy. The legitimate GHRH analog. EMA application withdrawn 2012.
• Ipamorelin. Selective GHS-R (ghrelin) agonist, never FDA-approved. Failed Phase 2 in postoperative ileus. Cat 2 since September 2023.
• CJC-1295 with DAC. Long-acting GHRH analog. ConjuChem's Phase 2 in HIV lipodystrophy was halted in July 2006 after a participant death (cause not formally adjudicated in the public record). Development abandoned.
• MOTS-c. A 16-amino-acid mitochondrial-derived peptide (Cohen lab, USC, 2015). Genuine mainstream research interest. CohBar took CB4211 to Phase 1, then dissolved in 2023. Solid mouse data, no human longevity trials.
• Humanin. A 24-amino-acid mitochondrial peptide (Hashimoto, 2003), mostly preclinical.
• Epitalon (AEDG). Tetrapeptide claimed to extend telomeres. Almost entirely from one Russian group (Khavinson, St Petersburg). Essentially zero independent Western replications.
• GHK-Cu. Copper tripeptide. Topical use (skincare) has decent small-trial data. Injectable use has no human RCTs.
• AOD-9604. GH fragment marketed for fat loss. Failed Phase 2b in 2007 (no significant weight effect at 24 weeks in n=536). Resurrected by clinics with no new evidence.
• Selank, Semax. Russian-registered prescription nootropics in Moscow. Everywhere else, research chemicals.
• Cerebrolysin. Porcine brain-derived peptide cocktail. Approved in around 50 countries (Austria included), not FDA. Cochrane reviews find weak, industry-funded evidence with benefit 'too small to be clinically meaningful'.

One-line summary: two of these are well-evidenced (tesamorelin, thymosin α1), one is mechanistically interesting and worth watching (MOTS-c), and most of the rest sit somewhere between 'promising in mice' and 'marketing'.

This is the section the longevity-clinic websites avoid.

Most grey-market longevity peptide protocols revolve around the GH/IGF-1 axis: sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677. They all do roughly the same thing. They push your pituitary to release more growth hormone, which then raises IGF-1 (insulin-like growth factor 1, the downstream signaling molecule) in the liver.

Here is the problem. The single most replicated finding in longevity biology points the other way: lower lifetime GH/IGF-1 signaling correlates with longer healthspan and longer life.

• C. elegans with daf-2 / IGF-1R loss-of-function mutations live up to twice as long (Kenyon, 1993).
• Ames and Snell dwarf mice (low GH because of a Prop-1 mutation) live up to 70 percent longer than wild-type mice (Bartke).
• The Guevara-Aguirre Ecuadorian Laron-syndrome cohort (humans with non-functioning GH receptors and near-zero IGF-1) has been followed for over 22 years. Despite obesity, the cohort shows essentially zero diabetes and one non-lethal cancer, versus 5 percent diabetes and 17 percent cancer in unaffected relatives (Sci Transl Med, 2011).
• Female centenarians with below-median IGF-1 have significantly longer survival (Milman & Barzilai, Aging Cell, 2014). FOXO3, which sits downstream of IGF-1R and switches on when IGF-1 signaling is low, is the most replicated longevity gene in humans.
• Acromegaly (the disease state of chronically high GH and IGF-1) raises cancer risk: thyroid cancer SIR around 7×, colorectal cancer SIR 1.95 (PLOS One 2023; JCEM 2018).

And one more wrinkle: in the 2023 update to the Hallmarks of Aging (López-Otín et al., Cell), 'disabled macroautophagy' was added as a standalone hallmark. GH-axis peptides activate mTORC1, which suppresses autophagy (your cells' built-in recycling program for damaged proteins). They push against this hallmark.

So picture this. A healthy adult paying €500-1500 per month at a clinic to pulse GHRH and ghrelin agonists, raise IGF-1 by 50-100 percent, activate mTORC1, and suppress autophagy is running the longevity experiment in reverse. The acute effects users notice (better sleep, leaner body composition, faster recovery) are real and short-term. The mechanism they activate is the one nature appears to down-regulate in long-lived humans and animals. There is no human RCT showing GH-axis peptides extend lifespan. The biology argues they may compress it.

The risks of grey-market peptide use are not theoretical. They have a body count.

Contamination and mislabeling. A 2024 study in the Journal of Medical Internet Research (Ashraf et al.) tested 'semaglutide' vials bought without prescription from three online vendors (SemaSpace, BiotechPeptides, USChemLabs). Measured polypeptide purity was 7.7 to 14.4 percent versus the ≥99 percent claimed. Bacterial endotoxin levels (bacterial debris that causes fever, sepsis, and septic shock when injected) ranged from 2.16 to 8.95 EU/mg, far above the USP threshold for parenteral injectables. Where semaglutide was present at all, actual semaglutide content exceeded the labelled dose by 28 to 39 percent, an overdose risk stacked on top of the impurity problem. (Heavy metals were not assessed in this study.) Independent assays of other 'research' peptide vials have found wrong amino-acid sequences, racemized D/L stereoisomers (a known immunogenicity driver), and Certificates of Analysis that turn out to be fabricated, copy-pasted between products, or attached to the wrong substance entirely.

Counterfeit GLP-1s. Three named events.

• WHO Medical Product Alert N°2 / 2024 (19 June 2024): falsified Ozempic batches LP6F832, NAR0074, and MP5E511 identified in the regulated supply chain in Brazil, the UK, and the US (Oct to Dec 2023). The WHO alert itself does not name the substituted ingredient, but parallel regulatory and press reporting (Austrian and Lebanese authorities, US case series) documented hospitalisations from severe hypoglycemia after counterfeit pens later confirmed to contain insulin instead of semaglutide.
• MHRA Birmingham notice (24 February 2026): five falsified Mounjaro KwikPen 15mg pens (batch D873576) identified at The Private Pharmacy Clinic after dose-knob faults. The clinic informed individual patients.
• Salford death (May 2025): Karen McGonigal, 53, of Salford (Greater Manchester) received an illegal £20 weight-loss injection from a beautician. The substance was reported as believed to be semaglutide. She was hospitalised four days after her last injection and died after two days in intensive care. Greater Manchester Police arrested two people on suspicion of manslaughter and supplying a controlled substance.

FAERS and FDA enforcement. As of December 31, 2024, the FDA Adverse Event Reporting System held more than 900 adverse events tied to compounded semaglutide and tirzepatide, including at least 11 confirmed deaths in FAERS through late 2024 (FAERS records exposure association, not causation; the Alliance for Pharmacy Compounding briefing cites 11 deaths, though other reporting windows have yielded higher counts up to 17). The dominant pattern was patients drawing 5 to 20× the intended dose from multidose vials. The FDA issued more than 50 warning letters to telehealth GLP-1 sellers in a single day on 16 September 2025, and dispatched another 30 letters on 20 February 2026 (publicly announced 3 March 2026). In an older 2020 plea agreement and 2021 sentencing, the Department of Justice obtained a $1.79 million criminal forfeiture against Tailor Made Compounding (Nicholasville, Kentucky) for distributing BPC-157 and 12 other unapproved peptides. That case predates the current FDA telehealth crackdown but remains the most-cited US precedent on unapproved-peptide forfeiture.

Systemic risks of GH-axis peptides. Acromegaly (the chronic-high-GH disease state these peptides simulate at supraphysiologic doses) raises cancer risk: thyroid cancer SIR around 7×, colorectal cancer SIR 1.95 (PLOS One 2023). Water retention, peripheral edema, carpal tunnel from median-nerve compression, insulin resistance, hypothyroidism, and pituitary axis suppression all show up in healthy users. A 24-week Phase IIb MK-677 trial in older adults at hip-fracture risk was terminated early because of excess heart failure (6.5% versus 1.7% placebo).

Pro-angiogenic peptides and cancer. BPC-157 and TB-500 work in part by stimulating angiogenesis (the growth of new blood vessels). VEGF/VEGFR2, the main pathway BPC-157 upregulates, is active in roughly half of human tumors. No human carcinogenicity data exists either way. The mechanism is the worry: you do not want to drive angiogenesis if there is anything malignant or pre-malignant in your body that you do not yet know about.

GLP-1 systemic risks. Even the FDA-approved versions carry real risks. A 2024 cohort study (Hathaway, Mass Eye and Ear, JAMA Ophthalmology) found a roughly 4× elevated risk of NAION (non-arteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss); cholelithiasis (RR 1.46); gastroparesis severe enough to delay anesthesia. EMA's PRAC reviewed and did not confirm a suicidality signal in April 2024.

Melanotan-II. Several peer-reviewed case reports document eruptive dysplastic nevi (sudden new abnormal moles), severe dysplasia on histology, and at least four melanomas arising in pre-existing nevi during or shortly after use.

Why peptides are harder to assess than small molecules. Short plasma half-lives prevent standard mass-balance and PK studies. Immunogenicity (your immune system mounting an antibody response to the peptide) is unpredictable batch-to-batch and can be life-threatening if the antibody cross-reacts with your own endogenous version. Modified peptides (DAC, PEGylation) have no established analytical reference standards. There is no FDA-approved clinical-pharmacology package for the vast majority of grey-market peptides. You are the Phase 1 subject.

Germany, Austria, and Switzerland all treat peptides as medicines, not supplements. That legal stance matters more than most buyers realize.

Germany. The relevant law is the Arzneimittelgesetz (AMG).

• § 73 AMG (Verbringungsverbot): prescription medicines cannot be mail-ordered to private individuals from outside the EU/EEA. This is not a grey zone. German Customs (Zoll) routinely seizes peptide shipments at airports and sends recipients an Anhörungsbogen (formal hearing notice). The Zollfahndungsamt München and the Munich prosecutor's office ran a coordinated 12-defendant peptide investigation in 2024-2025.
• § 95 AMG (Strafvorschriften): criminal penalties for placing unauthorized medicines on the market. Up to 3 years' imprisonment, up to 10 years for commercial or organized distribution.
• Personal travel supply (§ 73 Abs. 2 Nr. 6a): the only narrow exception. A traveller may carry up to a 3-month supply of a non-narcotic prescription drug personally in their luggage when entering Germany. This does not extend to postal orders.
• Anti-Doping-Gesetz (AntiDopG, 2015): criminalizes possession of nicht geringe Menge (non-trivial quantities) of substances on the WADA-derived prohibited list when held with doping intent (§ 4 Abs. 1 Nr. 4). Threshold quantities live in the Dopingmittel-Mengen-Verordnung (DmMV): GHRH analogs 180 mg, GHRP/GHS agonists 1.5 mg, IGF-1 analogs 3 mg. A typical vial of CJC-1295 exceeds the GHRH threshold. A typical vial of ipamorelin exceeds the GHRP threshold. Note the structure: § 4 Abs. 1 Nr. 1 to 3 (manufacture, distribution, sale) applies regardless of sport status. § 4 Abs. 1 Nr. 4 (possession of non-trivial quantities with doping intent) is restricted by § 4 Abs. 7 to Spitzensportler in an organised-sport Testpool or persons earning substantial sport income. For non-athletes, civil-criminal exposure for the same conduct usually runs through § 95 AMG, not AntiDopG.
• BPC-157 and TB-500 are not on the WADA-derived AntiDopG annex as of 2026. They fall under § 95 AMG instead. Same legal exposure, different statute.
• Heilpraktiker may not prescribe or administer prescription medicines (§ 48 AMG with HeilprG). Any Heilpraktiker offering injectable peptide therapy with prescription-grade compounds is operating outside their scope of practice.

Austria. The Arzneiwareneinfuhrgesetz 2010 (AWEG) prohibits private import of medicines from non-EU countries. Only public pharmacies may handle small imports under § 11. AGES (the Austrian medicines agency) takes the same line as BfArM.

Switzerland. Not in the EU. The Heilmittelgesetz (HMG, SR 812.21) Art. 20 (2)(a) lets private travellers import a maximum 1-month supply for personal use, stricter than Germany's 3 months. Mail-order to Swiss private individuals is prohibited by Swissmedic. In August 2025 Swissmedic published a public warning specifically about falsified GLP-1 and 'retatrutide kit' products sold on social media.

What is actually legal in DACH:

1. Buying an EMA-approved peptide (GLP-1, tesamorelin via private prescription, sermorelin via Apotheken-Rezeptur) at a German, Austrian, or Swiss pharmacy with a private prescription from a licensed physician.
2. Ordering from an EU mail-order pharmacy that holds the German Health Ministry's published mail-order licence, with a valid prescription, for substances authorized in either origin or destination country.
3. Carrying up to a 3-month personal supply (1 month for Switzerland) into the country in your hand luggage from another country.
4. Receiving compounded sermorelin via a German Rezeptur-Apotheke on private prescription. Typical cost: €150-300 per month.

Three common misconceptions:

• 'BPC-157 is legal in Germany because it's not in the BtMG.' False. Criminal liability comes from § 95 AMG, not the BtMG.
• 'AntiDopG never applies to me, I'm not a competitive athlete.' Partially false. Distribution and manufacturing offences (§ 4 Abs. 1 Nr. 1 to 3) apply to everyone. Possession of non-trivial quantities with self-doping intent (§ 4 Abs. 1 Nr. 4) is narrower. § 4 Abs. 7 limits criminal liability there to Spitzensportler in an organised-sport Testpool or persons earning substantial sport income. For civilians, the main criminal exposure for unauthorised peptides is § 95 AMG, not AntiDopG.
• 'Mail-order from any EU pharmacy is fine.' False. The supplier must be on the BMG-listed mail-order register, and the substance must be authorized.

For related grey-zone questions on ingestible compounds see the NMN Germany guide and the rapamycin Germany guide.

If the grey-market peptide story is mostly noise, the legitimate peptide pipeline is genuinely worth tracking.

Next-generation GLP-1 family. This is the only mature near-term story.

• Retatrutide (Lilly, a GLP-1 / GIP / glucagon triple agonist) reported 28.7 percent mean weight loss at 12 mg in TRIUMPH-4 (December 2025), with a separate signal of meaningful osteoarthritis pain relief. NDA expected late 2026.
• CagriSema (Novo, semaglutide combined with cagrilintide, an amylin analog) hit 22.7 percent in REDEFINE-1. Below Novo's 25 percent target and a stock-shock event in December 2024.
• Survodutide (Boehringer / Zealand, a GLP-1 / glucagon dual) achieved 16.6 percent at 76 weeks in SYNCHRONIZE-1 (April 2026), with parallel MASH trials.
• Orforglipron (Lilly) is the first oral small-molecule GLP-1 with injectable-comparable efficacy. ATTAIN-1 / ATTAIN-2 readouts in 2025-26, global submissions through 2026.

None of these trials use longevity endpoints. They all measure weight, A1C, cardiovascular events (SELECT: roughly 20% MACE reduction in non-diabetic obese), kidney outcomes (FLOW), MASH resolution (SYNERGY-NASH), sleep apnea (SURMOUNT-OSA, FDA approval December 2024). But the cardiometabolic spillover is functionally a longevity benefit: a single drug class now has hard outcome data on cardiovascular, renal, hepatic, sleep, and weight endpoints. Whether or not regulators ever label a drug 'anti-aging,' GLP-1s are quietly producing the first population-scale evidence of compressed morbidity from any pharmacological agent.

Pure-longevity peptide programs. All still preclinical.

• MOTS-c lost its industrial sponsor when CohBar dissolved in 2023.
• FOXO4-DRI (the proof-of-concept senolytic peptide that selectively kills senescent cells in aged mice; Baar et al., Cell 2017) is still pre-Phase 1 nine years on. Cleara Biotech is taking it forward.
• Klotho-domain KL1 has cognitive and renal-protective signals in models (Wyss-Coray group). No clinical-stage klotho peptide therapy yet.
• The TAME trial (the field's flagship attempt to run a real longevity RCT in humans, using metformin) remains only partially funded a decade after design. That one fact tells you why direct longevity peptide trials are rare. They are slow, expensive, and there is no FDA 'aging' indication to chase.

The biggest methodological step just landed. Validated 11-organ proteomic aging clocks (Wyss-Coray group, Nature Medicine and Nature Aging, 2025), built from plasma proteins (GDF15, FGF21, klotho-domain KL1, and others) measured across 44,498 UK Biobank participants. They predict heart failure, COPD, type 2 diabetes, and Alzheimer onset across organ systems. They are biomarkers, not therapies, but they may make 18-month longevity trials possible where 6-year composite-endpoint trials were the only option before. That is how peptide longevity research finally gets to scale.

Honest summary for 2026. Peptides have produced exactly two mechanistically credible longevity threads: mitochondrial-derived peptides (MOTS-c, humanin) and senolytic peptides (FOXO4-DRI). Both come with strong preclinical data and minimal human evidence. Most clinically marketed 'longevity peptides' are either mechanistically incoherent with established aging biology, dependent on a single non-replicated research group, or sold for cosmetic and recovery effects rebadged as life extension. More data is needed, and it is probably coming. Meanwhile the GLP-1 family is doing the actual work, on actual endpoints, in actual trials.